Thus, enhancing this natural counteracting force of steatosis through inhibition of key lipogenic activators via TRIM21-mediated ubiquitination may provide a therapeutic opportunity to treat NASH. This evidence concerns the gene TRIM21 and metabolic dysfunction-associated steatohepatitis.